Funding of PRRT (Lutate) in New South Wales

The Unicorn Foundation continues to advocate for greater access and funding for Peptide Receptor Radionuclide Therapy (PRRT).

In New South Wales, Dr John Leyden has been the consumer representative involved with the Agency of Clinical Innovations (ACI) Nuclear Medicine group development of 'Lutate therapy for NET patients in NSW' since 2010. The final submission was completed and submitted to the Minister for Health, Hon Jillian Skinner MP for consideration.

Dr John Leyden, on behalf of NSW NET cancer patients, met with NSW Health Senior Policy Advisor Cassandra Smith and ACI Chief Executive Dr Nigel Lyons to discuss the importance of and desperate need to fund Lutate in designated NSW public hospitals as per the proposal.

The Unicorn Foundation strongly urges all NSW NET patients, carers and friends to contact their local NSW Member of Parliament and request that they ask Health Minister Hon Jillian Skinner to fund Lutate therapy. We need this treatment and we need it now.

For more information to assist in this action, please contact Dr John Leyden at john.leyden@unicornfoundation.org.au

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

PBAC recommendation for selpercatinib a step forward for patient access

Expressions of interest open for ANZSNM nurse and allied health workshop in Canberra

NECA partners with Oncidium ahead of World Radiotheranostics Day 2026

ACCN Hosts Inaugural Regional, Rural and Remote Cancer Care Workshop in Dubbo

Our NET Nurses are here to help support you from diagnosis to treatment, and living well with NETs.

Free and confidential, our NET nurses are available Monday – Friday, 9am – 5pm (AEDT).